KalVista Presents Data Showing Sebetralstat Provides Relief for Hereditary Angioedema Attacks

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced the presentation of novel sebetralstat data related to laryngeal hereditary angioedema (HAE) attacks and adolescents with HAE at the American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) 2025 Joint Congress taking place in San Diego, CA from February 28–March 3, 2025.

"The growing body of data from the KONFIDENT-S study consistently demonstrate that sebetralstat enabled early treatment and fast symptom relief from HAE attacks, regardless of age, attack location, or severity," said Ben Palleiko, CEO of KalVista. "This is especially critical for vulnerable populations, such as those experiencing laryngeal attacks or adolescents whose only approved options are injectable on-demand treatments. Sebetralstat, if approved, would be the first oral on-demand treatment for HAE attacks, with the potential to address some of the most significant unmet needs in HAE and become the foundational therapy for HAE management."

Effectiveness of Sebetralstat for the On-demand Treatment of Laryngeal Hereditary Angioedema Attacks: Interim Analysis from KONFIDENT-S was presented byJonathan Bernstein, MD, FAAAAI, Professor of Clinical Medicine in the Department of Internal Medicine, Division of Allergy and Immunology at the University of Cincinnati College of Medicine; Partner at Bernstein Allergy Group and Clinical Research Center.

• 32 laryngeal attacks were treated with sebetralstat (September 14, 2024 cutoff)
• Median time to treatment with sebetralstat: 11.5 minutes after attack onset
• Median time to beginning of symptom relief: 1.27 hours
• 96% of those achieving beginning of symptom relief within 12 hours did so with a single dose
• No reports of difficulty swallowing film-coated tablet